Effectiveness of Transition from Intravenous Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic and Familial Pulmonary Arterial Hypertension

American Journal of Cardiology

Volumn 105, Issue 10, 2010, Pages 1485-1489

  Melnick, Laura ^a   Barst, Robyn J ^a   Rowan, Cherise A ^a   Kerstein, Diane ^a   Rosenzweig, Erika B ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ARTICLE; CHILD; CHILD HEALTH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EXERCISE; FAMILIAL PULMONARY ARTERIAL HYPERTENSION; FEMALE; FUNCTIONAL STATUS; HEMODYNAMICS; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; INFANT; INJECTIONS, INTRAVENOUS; MALE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951667237     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.075     Document Type: Article

References (20)

1. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
2. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Koerner S.K. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
3. Rubin L.J. Primary pulmonary hypertension. Chest 104 (1993) 236-250
4. Sandoval J., Bauerie O., Gomez A., Palomar A., Martinez Guerra M.L., and Guruya M.E. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 25 (1995) 466-474
5. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
6. Barst R.J., and Rosenzweig E.B. Pulmonary arterial hypertension in children: a medical update. Curr Opin Pediatr 20 (2008) 288-293
7. Channick R., Badesch D.B., Tapson V.F., Simonneau G., Robbins I., Frost A., Roux S., Rainisio M., Bodin F., and Rubin L.J. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 20 (2001) 262-263
8. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G., and Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
9. Haworth S.G., and Hislop A.A. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 95 (2009) 312-317
10. Beghetti M., Hoeper M.M., Kiely D.G., Carlsen J., Schwierin B., Segal E.S., and Humbert M. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 64 (2008) 200-204
11. Simonneau G., Rubin L.J., Galie N., Barst R.J., Fleming T.R., Frost A.E., Engel P.J., Kramer M.R., Burgess G., Collings L., Cossons N., Sitbon O., Badesch D.B., and PACES Study Group. Addition of sildenafil to long-term intravenous EPO therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530
12. Tulloh R. Management and therapeutic options in pediatric pulmonary hypertension. Expert Rev Cardiovasc Ther 4 (2006) 361-374
13. Depta J.P., and Krasuski R.A. Evidence-based medical management of pulmonary hypertension 2008: review of updated 2007 ACCP guidelines. Adv Pulm Hypertens (2008) 222-227
14. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
15. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., Brundage B.H., and Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous EPO (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
16. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
17. Shapiro S.M., Oudiz R.J., Cao T., Romano M.A., Beckmann X.J., Georgiou D., Mandayam S., Ginzton L.E., and Brundage B.H. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous EPO infusion. J Am Coll Cardiol 30 (1997) 343-349
18. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Hervé P., Rainisio M., and Simonneau G. Long-term intravenous EPO infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
19. Ivy D.D., Doran A., Claussen L., Bingaman D., and Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93 (2004) 943-946
20. Ivy D.D., Claussen L., and Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous EPO to intravenous treprostinil. Am J Cardiol 99 (2007) 696-698